CureVac N.V.

Frankfurt Stock Exchange:5CV.F

Sector

🏥 Health Care

Industries

💉 Vaccines

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Germany

Market Cap

USD 1.24 B

Share Price

USD 5.41

Avg Daily Volume

21,156

Change (1 day)

-0.90%

Change (1 year)

65.90%

Change (YTD)

76.39%

CureVac N.V. Free Cash Flow for the year ending December 31, 2024: USD 86.37 M

CureVac N.V. Free Cash Flow is USD 86.37 M for the year ending December 31, 2024, a -124.22% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

CureVac N.V. Free Cash Flow for the year ending December 31, 2023 was USD -356.61 M, a -12.15% change year over year.
CureVac N.V. Free Cash Flow for the year ending December 31, 2022 was USD -405.93 M, a -58.58% change year over year.
CureVac N.V. Free Cash Flow for the year ending December 31, 2021 was USD -980.15 M, a -268.90% change year over year.
CureVac N.V. Free Cash Flow for the year ending December 31, 2020 was USD 580.31 M, a -621.34% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

Frankfurt Stock Exchange: 5CV.F

CureVac N.V.

CEO	Dr. Alexander Zehnder M.B.A., M.D.
IPO Date	Aug. 14, 2020
Location	Germany
Headquarters	Friedrich-Miescher-Strasse 15
Employees	825
Sector	🏥 Health Care
Industries Vaccines 🧬 Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.